Positive Final Results in Stroke Study CUV801
Filed with ASX · · 4 pages · English
CLINUVEL today released positive final results of the open label pilot study (CUV801) in arterial ischemic stroke (AIS), evaluatingmultiple doses of CLINUVEL’s drug afamelanotide insix adult patients. Afamelanotide was shown to be well tolerated, with five of the six patients showing considerable clinical and functional recovery up to 42 days after treatment. "Final analyses from the CUV801 study
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- ACTH Manufacturing Update
- afamelanotide in Stroke (AIS) - Positive Preliminary Results
- CLINUVEL Reports December Half Year Operating Results
- Appendix 4D Half Year Report
- Response to ASX Price Query
Later from Clinuvel Pharmaceuticals
- Appendix 4E and Annual Report 2022
- S&P DJI Announces September 2022 Quarterly Rebalance
- Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4E and Annual Report to Shareholders 2023
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals